MIRM Mirum Pharmaceuticals, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core biopharma focused on rare diseases with three approved medicines: Livmarli, Cholbam, Ctexli
• • Acquired asset portfolios in 2023-2026: Travere’s bile acid medicines and Bluejay’s brelovitug for hepatitis D treatment
• • Strategic expansion into chronic HDV with brelovitug advancing in global Phase 3 AZURE program, topline data expected H2 2026
• • Livmarli approved in multiple countries for ALGS and PFIC; pursuing expanded indications with EXPAND Phase 3 study (results Q4 2026)
• • Brelovitug Phase 2 showed 100% virologic response at 48 weeks, granted FDA Breakthrough and EMA PRIME designations

Risk Factors

• • Regulatory risk CREATES Act compliance, sample provision obligations for generics under December 2019 law
• • Geopolitical/macro exposure in EU and U.S. orphan drug exclusivity potentially shortened by EU legislative proposals
• • Operational risk integration of Bluejay assets/employees critical to brelovitug development, potential disruption if integration fails
• • Competitive risk several companies including Shionogi and Harmony Biosciences developing therapies for fragile X syndrome
• • Financial risk dependence on key personnel amid fierce competition for talent in Foster City, CA with 369 full-time employees

What are the latest MIRM SEC filings in 2026?

Mirum Pharmaceuticals, Inc. (MIRM) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did MIRM file its most recent 10-K annual report?

Mirum Pharmaceuticals, Inc. (MIRM) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view MIRM 10-Q quarterly reports?

Mirum Pharmaceuticals, Inc. (MIRM)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every MIRM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has MIRM filed recently?

Mirum Pharmaceuticals, Inc. (MIRM)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find MIRM insider trading activity (Form 4)?

SignalX aggregates every MIRM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does MIRM file with the SEC?

Mirum Pharmaceuticals, Inc. (MIRM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new MIRM filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Mirum Pharmaceuticals, Inc. (MIRM).

What is MIRM's SEC CIK number?

Mirum Pharmaceuticals, Inc. (MIRM)'s SEC CIK (Central Index Key) number is 1759425. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1759425 to look up all MIRM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find MIRM return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Mirum Pharmaceuticals, Inc. (MIRM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.